Allergan, Inc.  

(Public, NYSE:AGN)   Watch this stock  
Find more results for Allergan Inc
170.49
+0.29 (0.17%)
Real-time:   9:36AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 169.88 - 170.93
52 week 87.88 - 174.49
Open 170.83
Vol / Avg. 0.00/1.97M
Mkt cap 50.64B
P/E 39.06
Div/yield 0.05/0.12
EPS 4.37
Shares 297.18M
Beta 0.74
Inst. own 94%
Oct 27, 2014
Q3 2014 Allergan Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 21, 2014
Q2 2014 Allergan Inc Earnings Call
Jul 21, 2014
Q2 2014 Allergan Earnings Release
Jun 30, 2014
Allergan Inc Conference Call to Announces R&D Pipeline Update and U.S. FDA Approval
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 22.44% 20.20%
Operating margin 32.61% 28.72%
EBITD margin - 34.67%
Return on average assets 15.46% 12.88%
Return on average equity 24.97% 20.63%
Employees 11,700 -
CDP Score - 91 B

Address

2525 Dupont Drive
IRVINE, CA 92612
United States - Map
+1-714-2464500 (Phone)
+1-714-2466987 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Allergan, Inc. is a multi-specialty health care Company focused on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products. The Company�s segments include specialty pharmaceuticals, which produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth and other prescription and over-the-counter skin care products; and urologic products and the medical devices segment, which produces a range of medical devices, including breast implants for augmentation, revision and reconstructive surgery and tissue expanders; obesity intervention products, and facial aesthetics products. In April 2014, TauTona Group�s subsidiary Aline Aesthetics has completed the sale of its Aline hyaluronic acid (HA) thread technology to Allergan, Inc.

Officers and directors

David E. I. Pyott Chairman of the Board, Chief Executive Officer, Principal Executive Officer
Age: 60
Bio & Compensation  - Reuters
Douglas S. Ingram Esq. President
Age: 51
Bio & Compensation  - Reuters
James M. Hindman Chief Financial Officer, Executive Vice President - Finance and Business Development
Age: 54
Bio & Compensation  - Reuters
Scott M. Whitcup M.D. Executive Vice President - Research & Development, Chief Scientific Officer
Age: 54
Bio & Compensation  - Reuters
Arnold A. Pinkston Executive Vice President, General Counsel, Assistant Secretary
Age: 55
Bio & Compensation  - Reuters
Scott D. Sherman Executive Vice President - Human Resources
Age: 48
Bio & Compensation  - Reuters
Raymond H. Diradoorian Executive Vice President - Global Technical Operations
Age: 56
Bio & Compensation  - Reuters
James F. Barlow Senior Vice President, Corporate Controller, Principal Accounting Officer
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Julian S. Gangolli Corporate Vice President and President, North America
Age: 56
Bio & Compensation  - Reuters
Michael R. Gallagher Lead Independent Director
Age: 68
Bio & Compensation  - Reuters